Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

Bibliographic Details
Main Authors:	Toshihiko Matsumoto, Tatsuki Ikoma, Shogo Yamamura, Kou Miura, Takao Tsuduki, Takanori Watanabe, Hiroki Nagai, Masahiro Takatani, Hisateru Yasui
Format:	Article
Language:	English
Published:	Nature Portfolio 2023-07-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-023-39009-5

Internet